(NASDAQ: WHWK) Whitehawk Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.44%.
Whitehawk Therapeutics's earnings in 2026 is -$115,806,000.On average, 10 Wall Street analysts forecast WHWK's earnings for 2026 to be -$61,899,648, with the lowest WHWK earnings forecast at -$84,810,974, and the highest WHWK earnings forecast at -$51,405,835. On average, 9 Wall Street analysts forecast WHWK's earnings for 2027 to be -$60,099,578, with the lowest WHWK earnings forecast at -$87,234,145, and the highest WHWK earnings forecast at -$43,097,822.
In 2028, WHWK is forecast to generate -$58,744,581 in earnings, with the lowest earnings forecast at -$84,810,974 and the highest earnings forecast at -$28,039,547.